Hologic Selenia Dimensions C-View Software Module. October 24, 2012
|
|
- Jayson Tate
- 8 years ago
- Views:
Transcription
1 Hologic Selenia Dimensions C-View Software Module October 24, 2012
2 Introduction and Agenda Peter Soltani, Ph.D. Senior VP & GM, Breast Health Hologic, Inc.
3 Agenda Technology Overview Clinical Overview Clinical Study Design Clinical Study Results Risk/Benefit Summary 3
4 Presenters Peter Soltani, Ph.D. Senior VP & GM, Breast Health Hologic, Inc. Andrew Smith, Ph.D. VP, Advanced Imaging Science Hologic, Inc. Loren Niklason, Ph.D. Director, Tomosynthesis Programs Hologic, Inc. Elizabeth A. Rafferty, M.D. Director, Breast Imaging Avon Comprehensive Breast Center Massachusetts General Hospital 4
5 Hologic and External Experts Jay A. Stein, Ph.D. Chief Technology Officer Hologic, Inc. Zhenxue Jing, Ph.D. Senior Vice President & Chief Science Officer Hologic, Inc. Arthur Friedman Senior Vice President, RA, QA, Clinical Hologic, Inc. Elkan Halpern, Ph.D. Director of Statistics, Institute of Technology Assessment Statistical Consultant, Radiology, RSNA 5
6 Technology Overview Andrew Smith, Ph.D. Vice President, Imaging Science Hologic, Inc.
7 Nomenclature Shorthand 2D FFDM 3D 2D plus 3D, Combo C-View, Synthesized 2D 3Ds, 3D plus C-View Definition Conventional digital mammography Tomosynthesis 2D digital mammogram and tomosynthesis images are acquired: currently approved tomosynthesis screening indication A projectional 2D image calculated from the 3D dataset. Does not require additional radiation exposure. Only tomosynthesis images are acquired, and a synthesized 2D image is created. Both are read together. This is the proposed new screening indication for use. 7
8 Selenia Dimensions 8
9 Tomosynthesis Screening Imaging 3D Reconstruct Tomo Slices Imaging 2D Review 3D + 2D Current combo mode Imaging 3D Reconstruct Tomo Slices Synthesize C-View Review 3D + C-View Proposed additional optional mode 3D plus C-View 9
10 How does it work? Perform a standard tomosynthesis scan (existing product) 10
11 ~60 Tomosynthesis Slices How does it work? Perform a standard tomosynthesis scan (existing product) Reconstruct tomosynthesis slices (existing product) Reconstruction Algorithm 15 Projection Images 11
12 ~60 Tomosynthesis Slices How does it work? Perform a standard tomosynthesis scan (existing product) Reconstruct tomosynthesis slices (existing product) Synthesize 2D image (C- View) Similar to Maximum Intensity Projection (MIP) as done with MRI images Image Summation C-View 12
13 13
14 Synthesized 2D Image Usage C-View is part of the 3D data set Image is identified, to avoid confusion with true 2D image 14
15 15
16 System Changes The synthesized 2D algorithm is a software module New 3D plus C-View mode is an option Optional mode available along with existing 2D plus 3D modes 16
17 Current Intended Use Statement (The same clinical applications as the commercially available 2D and/or 3D system) The Hologic Selenia Dimensions system generates digital mammographic images that can be used for screening and diagnosis of breast cancer. The Selenia Dimensions (2D or 3D) system is intended for use in the same clinical applications as a 2D mammography system for screening mammograms. Specifically, the Selenia Dimensions system can be used to acquire 2D digital mammograms and 3D mammograms. 17
18 Current Intended Use Statement (cont.) (The same clinical applications as the commercially available 2D and/or 3D system) Each view in a screening examination will consist of: a 2D image set, or a 2D and 3D image set The Selenia Dimensions system may also be used for additional diagnostic workup of the breast. 18
19 Proposed Intended Use Statement (cont.) (The same clinical applications as the commercially available 2D and/or 3D system) Each view in a screening examination will consist of: a 2D image set, or a 2D and 3D image set, or a 3D image set in combination with a synthesized 2D image The Selenia Dimensions system may also be used for additional diagnostic workup of the breast. 19
20 Breast Tomosynthesis: Clinical Benefit Elizabeth A. Rafferty, M.D. Director, Breast Imaging Avon Comprehensive Breast Center Massachusetts General Hospital
21 Mammography Prompt annual mammography has shown the ability to reduce the mortality rate from breast cancer in a population by 15% to 50%. 1-3 As many as 20% of breast cancers will be missed by mammography. Approximately 10% of women are recalled for additional workup and a significant portion prove to have no abnormality, resulting in unnecessary anxiety and cost. 1. Smith RA, Duffy SW, Gabe R et al. The randomized trials of breast cancer screening: what have we learned? Radiol Clin N Am 42 (2004) Hendrick RE, Smith RA, Rutledge JH, Smart CR. Benefit of screening mammography in women ages 40-49: a new meta-analysis of randomized controlled trials. Monogr Natl Cancer Inst 1997;22: Tabar L, Vitak B, Chen T H-H, Yen MF, Duffy SW, Smith RA. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 2001;91:
22 Mammography Limitations A major factor contributing to the limited performance of mammography is the tissue superimposition that is created by the overlap of normal breast structures in a two-dimensional mammographic projection. These overlapping structures can obscure a lesion making it more difficult to perceive or rendering it completely mammographically occult. 22
23 RMLO 2D 23
24 Mammography Limitations A major factor contributing to the limited performance of mammography is the tissue superimposition that is created by the overlap of normal breast structures in a two-dimensional mammographic projection. These overlapping structures can obscure a lesion making it more difficult to perceive or rendering it completely mammographically occult. By mimicking mammographic lesions, overlapping structures can also generate false positive findings at screening, resulting in unnecessary recalls. 24
25 2D 25
26 Anticipated Benefits of 3D Increased breast cancer detection Decreased recall rate for non-cancer cases Improved lesion margin visibility Precise lesion localization 26
27 RMLO 2D 27
28 2D 3D 28
29 RCC RCC 2D 3D 29
30 Slice
31 Benefits of 2D plus 3D Combined digital mammography and breast tomosynthesis approved for clinical use by the FDA on February 11,
32 Benefits of 2D plus 3D Study 1 2D plus 3D Study 1 2D Study 2 2D plus 3D Study 2 2D Radiology. In press. 32
33 Benefits of 2D plus 3D At the 98 th Scientific Assembly and Annual Meeting of the Radiological Society of North America scheduled for November of 2012: 9 abstracts will be presented detailing the positive benefits of combined digital mammography and breast tomosynthesis for both screening and diagnostic applications in the clinical environment. 33
34 2D plus 3D Dose While evidence of the clinical benefits of 3D are accruing, attention has also been drawn to the incremental increase in dose over 2D FFDM. Phantom Dose (mgy) FDA MQSA Dose Limit The imaging community is always striving to minimize dose while maintaining quality D 2D plus 3D MLO 2D plus 3D 34
35 2D plus 3D Dose One strategy for reducing dose is to perform only the 3D MLO in addition to the 2D FFDM Study 1 2D plus 3D Study 1 2D Study 2 2D plus 3D Study 2 2D Study 2 2D plus 3D MLO 35
36 Rationale for 3D plus C-View
37 Rationale for 3D plus C-View The advantage of two-view tomosynthesis suggests an alternative strategy to reducing dose while capitalizing on the benefits of 3D: elimination of the 2D mammogram. In interpreting the 3D study, there is value to having a 2-dimensional summary image available to the radiologist: Assessment of side to side symmetry 37
38 RCC LCC 2D FFDM 38
39 RCC LCC 39
40 RMLO LMLO 2D FFDM 40
41 RMLO LMLO 41
42 Rationale for 3D plus C-View The advantage of two-view tomosynthesis suggests an alternative strategy to reducing dose while capitalizing on the benefits of 3D: elimination of the 2D mammogram. In interpreting the 3D study, there is value to having a 2-dimensional summary image available to the radiologist: Assessment of side to side symmetry Assessment of interval change 42
43 43
44 44
45 Assessment of Interval Change The aesthetic of the C-View image may be different This is commonly encountered in clinical practice Comparing digital mammography with analog prior imaging Comparing digital mammography with prior imaging from a different vendor Comparing digital mammography with prior imaging using different processing algorithms This situation presents itself whenever technology changes 45
46 Rationale for 3D plus C-View The advantage of two-view tomosynthesis suggests an alternative strategy to reducing dose while capitalizing on the benefits of 3D: elimination of the 2D mammogram. In interpreting the 3D study, there is value to having a 2-dimensional summary image available to the radiologist: Assessment of side to side symmetry Assessment of interval change Detection of calcifications 46
47 Calcification Detection: Case 1
48 LMLO 2D FFDM 48
49 LMLO 49
50 2D FFDM C-View 3D Slices 50
51 Calcification Detection: Case 2
52 MLO CC 2D FFDM C-View 3D Slice 52
53 Calcification Detection: Case 3
54 2D FFDM C-View 3D Slice 54
55 Calcification Detection: Case 4
56 2D FFDM C-View Tomosynthesis 56
57 Rationale for 3D plus C-View The advantage of two-view tomosynthesis suggests an alternative strategy to reducing dose while capitalizing on the benefits of 3D: elimination of the 2D mammogram. In interpreting the 3D study, there is value to having a 2-dimensional summary image available to the radiologist: Assessment of side to side symmetry Assessment of interval change Detection of calcifications Recognition of the distributional aspect of features (particularly calcifications) 57
58 RCC 2D FFDM
59 RCC
60 2D FFDM C-View Tomosynthesis
61 Rationale for 3D plus C-View 3D plus C-View imaging provides another lower dose tomosynthesis imaging option for the radiologist. Our study was designed to compare the diagnostic accuracy of 3D plus C-View to the current standard: 2D FFDM. 61
62 Clinical Study Overview
63 Study Design Image Acquisition Cases were accrued from 22 sites in the United States under IRB approval with written informed consent Subjects presented for either screening or biopsy Subjects underwent investigational 2D and 3D imaging (in a single compression) of both breasts in the MLO and CC views Screening subjects also underwent standard of care 2D FFDM imaging (SOC) on the same day Biopsy subjects were eligible for the study if their SOC imaging had been performed within the past 60 days. SOC imaging and investigational imaging were interpreted by different radiologists at the accruing sites 63
64 Enrollment Exclusion Criteria Women with a prior excisional biopsy Women with an internal breast marker Women with breast implants Breasts too large to be imaged in a single compression 64
65 Enrollment Exclusion Criteria Prior excisional biopsy 65
66 Enrollment Exclusion Criteria Prior excisional biopsy Presence of an internal tissue marker 66
67 Enrollment Exclusion Criteria Prior excisional biopsy Presence of an internal tissue marker Breast implants 67
68 Enrollment Exclusion Criteria Prior excisional biopsy Presence of an internal tissue marker Breast implants 68
69 Enrollment Exclusion Criteria Prior excisional biopsy Presence of an internal tissue marker Breast implants Breasts too large to be imaged in a single compression 69
70 Study Design Case Selection Eligible collected cases were classified into one of 4 categories: 1. Malignant (biopsy-proven) 2. Benign (biopsy-proven) 3. Recalled from screening Based on either the reading of the SOC or investigational imaging 4. Negative Based on a negative interpretation of both the SOC and investigational imaging REFERENCE STANDARD: Malignant cases: pathology Non-malignant cases: one year follow up to confirm non-malignant status 70
71 QC Exclusion Criteria 3521 Subjects imaged 536 Excluded at site level 2985 Eligible cases after site exclusions 590 Excluded at QC 96 Excluded for use in a pilot study and exclusions based on reader study criteria 2299 Eligible Subjects 1997 Not randomized for reader study 302 Randomized into study 71
72 QC Exclusion Criteria Entire case was excluded if any of the 8 images acquired failed to pass QC Acquisition protocol did not allow for repeat imaging Quality Control exclusions Patient motion Positioning Gridlines or artifacts Approximately 3% of images excluded Number of 2D FFDM and 3D exclusions rates ~ equal 19.8% (590/2985) cases excluded Age, breast density and ethnicity of cases excluded were very similar to cases included 72
73 Overview of Reader Study Comparison of 3Ds to 2D FFDM Retrospective enriched reader study (crossed design with one month delay) 302 cases reviewed by 15 radiologists Readers were MQSA qualified with a wide range of experience with 2D and 3D Primary Endpoint: Receiver-operator characteristic (ROC) area under the curve (AUC) performance for 3Ds imaging is non-inferior to that of 2D FFDM Secondary Endpoints: ROC AUC for subjects with dense breasts using 3Ds is non-inferior to that of 2D FFDM The non-cancer recall rate for 3Ds is non-inferior to that of 2D FFDM 73
74 Reader Study Cohort Calcification Cases Non-Calcification Cases All Cases Benign Cancer Recall (32%) 120 (68%)
75 Reader Study Cohort Calcification Cases Non-Calcification Cases All Cases Benign Cancer Recall Negative 126 Total
76 Study Design Case Selection BIRADS Density 1 BIRADS Density 2 BIRADS Density 3 BIRADS Density 4 Cases were selected to give an approximate 50/50 mix of fatty vs dense parenchymal patterns 76
77 Inherent Case Selection Bias The vast majority of the cancers included in the reader study came from the biopsy cohort (4 came from screening cohort) and had already been diagnosed by conventional methods prior to enrollment. This method of case selection biases the study against demonstrating a gain in sensitivity using 3D plus C-View because nearly all of the cancers were detected with FFDM imaging. Sensitivity was not an endpoint of the study given the case selection bias. 77
78 Study Design Readers 15 readers participated in the study All readers were MQSA qualified Based on their experience, readers were classified into 3 categories: 1. High volume: interprets > 5000 mammograms / year 2. Medium volume: interprets between 3000 and 5000 mammograms / year 3. Low volume: interprets 3000 mammograms / year or less Additionally, readers were asked whether they had prior clinical experience interpreting tomosynthesis imaging. 78
79 Reader Experience Reader # Mammography exams per year Tomosynthesis Experience Y Y N Y N Y N N Y Y N Y Y N N 79
80 Study Design Reader Training Training focused on the interpretation of 3D images: Normal anatomy Resolution of summation artifact Appearance of masses, architectural distortion and calcifications C-View images were presented with each training case reviewed Emphasis was placed on the use of the C-View image functioning as an overview to guide interpretation of the 3D data set Analogous to a MIP image in MRI 80
81 Study Design Reader Training Training focused on the interpretation of 3D images: Normal anatomy Resolution of summation artifact Appearance of masses, architectural distortion and calcifications C-View images were presented with each training case reviewed Readers read 2 assessment sets and performance thresholds were measured for assessment set 2 In total the readers reviewed approximately 150 cases for training purposes No training cases were used in the Reader Study 81
82 Study Design Reader Case Review 302 cases 2D FFDM and 3Ds Session 1 2D FFDM (151) Session 1 3D s (151) 1 month washout Session 2 3D s (151) Session 2 2D FFDM (151) Data Analysis 82
83 Study Design Reader Case Review Scoring was lesion-based Only lesions deemed actionable were marked Up to 3 lesions could be marked per case Lesion location was recorded for each lesion Lesion type (calcification, non-calcification or both) was recorded for each lesion Scoring: Initial BIRADS: 0, 1, or 2 Forced BIRADS: 1 to 5 score for all BIRADS 0 cases Probability of Malignancy: 0% to 100% for all cases 83
84 Data Analysis Loren Niklason, Ph.D. Director, Tomosynthesis Programs Hologic, Inc.
85 Study Design Study Endpoints Primary Endpoint: ROC AUC performance for 3Ds imaging is noninferior to that of 2D FFDM Delta 5% Probability of malignancy (POM) scores used for ROC analysis p < 0.05 considered significant difference, prospectively defined Retrospective enriched ROC study design similar to FDA approval studies for 2D plus 3D and 2D FFDM systems 85
86 Study Design Study Endpoints Primary Endpoint: ROC AUC performance for 3Ds imaging is noninferior to that of 2D FFDM Secondary Endpoints: ROC AUC for subjects with dense breasts using 3Ds is non-inferior to that of 2D FFDM Delta 5% Probability of malignancy (POM) scores used for ROC analysis 86
87 Study Design Study Endpoints Primary Endpoint: ROC AUC performance for 3Ds imaging is noninferior to that of 2D FFDM Secondary Endpoints: ROC AUC for subjects with dense breasts using 3Ds is non-inferior to that of 2D FFDM The non-cancer recall rate for 3Ds is non-inferior to that of 2D FFDM Delta 5%, all non-cancer cases included 87
88 Recall Rate Analysis Non-Cancer Cases Analysis of recall rate was performed for individuals and for all readers using a bootstrapping analysis Bootstrapping analysis allows determination of confidence limits based on randomly selecting new samples of readers and cases from the original sample. 88
89 ROC Curves Higher Recall Rate Higher Cancer Detection Lower Recall Rate Lower Cancer Detection 89
90 ROC Curves AUC Difference System 2 System 1 Area Under Curve System #1 90
91 ROC Curves System 2 System 1 91
92 Clinical Reader Study Results Elizabeth A. Rafferty, M.D. Director, Breast Imaging Avon Comprehensive Breast Center Massachusetts General Hospital
93 Results Reader Inclusion Pre-determined thresholds for reader performance had been determined for 2D FFDM and 3Ds Application of the pre-determined thresholds resulted in several of the radiologists not meeting criteria for inclusion in the data analysis (predominantly based on their interpretation of the 2D FFDM) After discussions with the FDA, it was decided to include all 15 readers in the analysis Subsequent data analysis confirmed nearly identical outcomes regardless of the thresholding standards applied. 93
94 Results Primary Endpoint ROC AUC performance for 3Ds imaging is non-inferior to that of 2D FFDM 94
95 ROC AUC: All Cases, All Readers ROC AUC Difference Reader 2D 3D S 3D S -2D FFDM Mean One Sided 95% CI Lower Limit p-value
96 Mean ROC curves: All Cases, All Readers AUC D = p =
97 Primary Endpoint ROC AUC performance for 3Ds imaging is non-inferior to that of 2D FFDM Using multi-reader, multi-case ROC analysis, 3Ds imaging was non-inferior to 2D FFDM In fact, 3Ds imaging was superior to 2D FFDM 14 out of 15 radiologists demonstrated improved AUC with 3Ds compared to 2D FFDM 97
98 RMLO 2D FFDM 98
99 RMLO 99
100 2D FFDM 6/15 readers recalled 100
101 2D FFDM mean POM: 8.5% 101
102 C-View 3D Slice 15/15 readers recalled 102
103 C-View 3D Slice mean POM: 91.3% 103
104 Primary Endpoint ROC AUC performance for 3Ds imaging is non-inferior to that of 2D FFDM Using multi-reader, multi-case ROC analysis, 3Ds imaging was non-inferior to 2D FFDM In fact, 3Ds imaging was superior to 2D FFDM 14 out of 15 radiologists demonstrated improved AUC with 3Ds compared to 2D FFDM The primary endpoint was met. 104
105 Secondary Endpoints ROC AUC for subjects with dense breasts using 3Ds is non-inferior to that of 2D FFDM 105
106 ROC AUC; Dense Breast Cases, All Readers ROC AUC Difference 3D S Reader 2D 3D S -2D FFDM Mean One Sided 95% CI Lower Limit p-value
107 Mean ROC curves; Dense Breast Cases, All Readers AUC D = p =
108 Secondary Endpoint Dense Breasts ROC AUC for subjects with dense breasts using 3Ds is noninferior to that of 2D FFDM Using multi-reader, multi-case ROC analysis, 3Ds imaging was non-inferior to 2D FFDM 14 out of 15 radiologists demonstrated improved AUC with 3Ds compared to 2D FFDM 108
109 LMLO 2D FFDM
110 LMLO
111 2D FFDM 4/15 readers recalled
112 2D FFDM mean POM: 14.4%
113 C-View 3D Slice 10/15 readers recalled
114 C-View 3D Slice mean POM: 46.1%
115 Secondary Endpoint Dense Breasts ROC AUC for subjects with dense breasts using 3Ds is noninferior to that of 2D FFDM Using multi-reader, multi-case ROC analysis, 3Ds imaging was non-inferior to 2D FFDM 14 out of 15 radiologists demonstrated improved AUC with 3Ds compared to 2D FFDM This secondary endpoint was met. 115
116 Secondary Endpoint Non-cancer recall rate The non-cancer recall rate for 3Ds is non-inferior to that of 2D FFDM 116
117 Recall Rates: Non-Cancer Cases (Recalls, Negatives, Benign) Reader 2D FFDM Recalls 3D S Recalls Number Cases 2D FFDM Recall rate 3D S Recall rate Difference 3DS-2DFFDM % 36.4% -7.2% % 37.3% -31.6% % 23.6% -11.5% % 17.8% -9.3% % 23.6% -7.5% % 30.7% -19.1% % 36.9% -18.2% % 27.6% -9.3% % 33.8% -17.3% % 42.2% -9.4% % 38.7% -14.2% % 33.3% -14.3% % 22.2% -16.0% % 42.7% -10.2% % 35.1% -12.5% Total/Mean 1551/ / % 32.1% -13.9% On average, readers reduced the number of cases recalled using 3Ds compared to 2D FFDM by 31 cases Relative reduction in recall rate was 30% 117
118 Recall Rates: Screening Cases (Recalls, Negatives) 2D FFDM Number 2D FFDM 3D S Recall Difference Reader Recalls 3D S Recalls Cases Recall rate rate 3DS-2DFFDM % 26.0% -6.0% % 22.7% -38.0% % 10.0% -14.0% % 8.0% -11.3% % 13.3% -9.4% % 19.3% -18.0% % 24.0% -19.3% % 15.3% -10.0% % 22.7% -16.6% % 28.7% -10.0% % 27.3% -14.0% % 22.7% -16.0% % 12.7% -16.6% % 34.0% -8.0% % 25.3% -11.4% Total/Mean 796/53 468/ % 20.8% -14.6% On average, readers reduced the number of cases recalled using 3Ds compared to 2D FFDM by 22 cases Relative reduction in recall rate was 41% 118
119 Secondary Endpoint Non-cancer recall rate The non-cancer recall rate for 3Ds is non-inferior to that of 2D FFDM Using bootstrapping analysis, this secondary endpoint was met and 3Ds was non-inferior to 2D FFDM In fact, 3Ds was superior to 2D FFDM 15 of 15 radiologists had a statistically significant reduction in non-cancer recall rate 119
120 RCC 2D FFDM
121 RCC
122 2D FFDM 11/15 readers recalled
123 Tomosynthesis C-View 2/15 readers recalled Tomosynthesis
124 Secondary Endpoint Non-cancer recall rate The non-cancer recall rate for 3Ds is non-inferior to that of 2D FFDM Using bootstrapping analysis, this secondary endpoint was met and 3Ds was non-inferior to 2D FFDM In fact, 3Ds was superior to 2D FFDM 15 of 15 radiologists had a statistically significant reduction in non-cancer recall rate This secondary endpoint was met. 124
125 Summary of Endpoints The primary endpoint was met 3Ds was shown to be superior to 2D FFDM for the primary endpoint: diagnostic accuracy for all cases The secondary endpoints were met 3Ds was shown to be non-inferior to 2D FFDM for the secondary endpoint of diagnostic accuracy in dense breast cases 3Ds was shown to be superior to 2D FFDM for the secondary endpoint of non-cancer recall rate 125
126 Risk Benefit Analysis
127 Benefits of Mammography Clinical Trials have demonstrated that screening mammography reduces breast cancer mortality by 15% to 50% 1-3 These numbers are conservative 1-view vs. 2-view mammography Annual vs. biennial screening Compliance and contamination Limited number of screening rounds Advances in technology 1. Smith RA, Duffy SW, Gabe R et al. The randomized trials of breast cancer screening: what have we learned? Radiol Clin N Am 42 (2004) Hendrick RE, Smith RA, Rutledge JH, Smart CR. Benefit of screening mammography in women ages 40-49: a new meta-analysis of randomized controlled trials. Monogr Natl Cancer Inst 1997;22: Tabar L, Vitak B, Chen T H-H, Yen MF, Duffy SW, Smith RA. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 2001;91:
128 Summary of Screening Benefits Likely mortality reduction is at least 30% - 50%* * EUROSCREEN Working Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. Med Screen, September 2012, Vol. 19 [Suppl 1], pp
129 Risk Analysis Estimates of the lifetime mortality risk from annual mammography from age 40-80: 2D FFDM: D plus C-View: Hendrick RE. Radiation Doses and Cancer Risks from Breast Imaging Studies, Radiology 257: ,
130 ACR Phantom Dose FDA MQSA dose limit D FFDM 2D FFDM 2D FFDM 2D FFDM 3D + (Hologic) (MQSA*) + 3D-MLO + 3D C-View *Mourad WG. Average Glandular Dose in FDA-approved FFDM Systems (2005) 130
131 Additional Analyses
132 Additional Analyses Calcification cases versus non-calcification cases ROC analysis 132
133 Mean ROC curves All Readers Calcification vs Non-Calcification Cases Non-Calcification Cases AUC D = p = /15 readers improved with 3Ds 133
134 Mean ROC curves All Readers Calcification vs Non-Calcification Cases Non-Calcification Cases Calcification Cases AUC D = p =.011 AUC D = p = /15 readers improved with 3Ds 134
135 2D FFDM 13/15 readers recalled 135
136 2D FFDM C-View 3D Slice 15/15 readers recalled 136
137 Additional Analyses Calcification cases versus non-calcification cases ROC analysis Fatty breasts - ROC analysis 137
138 Mean ROC curves All Readers Fatty Breast Cases AUC D = p = /15 readers improved with 3Ds 138
139 139
140 140
141 RCC 2D FFDM 141
142 RCC 142
143 2D FFDM 8/15 readers recalled 143
144 2D FFDM mean POM: 14.4% 144
145 2D FFDM C-View Tomosynthesis 13/15 readers recalled 145
146 2D FFDM C-View Tomosynthesis mean POM: 60.1% 146
147 Additional Analyses Calcification cases versus non-calcification cases ROC analysis Fatty breasts - ROC analysis Cancer recall analysis 147
148 Cancer Recalls with Correct Location and Lesion Type Reader 2D FFDM Recalls 3D S Recalls Number Cases 2D FFDM Recall rate 3D S Recall rate Difference 3Ds-2D FFDM % 79.2% -2.6% % 90.9% 0.0% % 84.4% 0.0% % 80.5% 7.8% % 80.5% 1.3% % 87.0% 2.6% % 85.7% -2.6% % 85.7% 7.8% % 84.4% 0.0% % 84.4% 0.0% % 90.9% 10.4% % 88.3% 5.2% % 80.5% 3.9% % 89.6% 5.2% % 87.0% 5.2% Total/Mean 951/ / % 85.3% 3.0% 148
149 Additional Analyses Calcification cases versus non-calcification cases ROC analysis Fatty breasts - ROC analysis Cancer recall analysis Distribution of cases potential for bias based on types of cases included 149
150 Distribution of Cases FDA questioned the impact of case mix on the outcome of this study The 3Ds study has more negatives and more cancer cases than our previous 2D plus 3D PMA study 150
151 Distribution of Cases 2D plus 3D Cancer Benign Recall Negatives 3Ds Cancer Benign Recall Negatives 151
152 Distribution of Cases FDA questioned the impact of case mix on the outcome of this study The 3Ds study has more negatives and more cancer cases than our previous 2D plus 3D PMA study Analyses were done to determine if results change as a function of case distribution: All Cases Cancer + recall Cancer + negative Cancer + benign + negative Cancer + benign + recall (more similar to 2D plus 3D case mix) 152
153 Analyses of Results with Different Case Distributions Case Distribution 2D FFDM AUC 3Ds AUC Difference 3Ds -2D FFDM Number Cases One sided 95% CI Lower Limit p-value All Cancer + recalls Cancer + negatives Cancer + benign + recall Cancer + benign + negatives All differences in AUC ~.04 regardless of case distribution and all are significant. 153
154 Summary
155 Summary All primary and secondary endpoints were met or exceeded. 3D plus C-View is a two-view tomosynthesis imaging option that is superior to 2D FFDM at a comparable dose. 155
156 LMLO 2D FFDM 156
157 LMLO 157
158 2D FFDM 5/15 readers recalled 158
159 2D FFDM mean POM: 4.9% 159
160 C-View 3D Slice 15/15 readers recalled 160
161 C-View 3D Slice mean POM: 94.9% 161
162 Conclusion The data from our reader study has demonstrated that 3D plus C-View is effective for clinical use. The analysis of benefits and risk for 3D plus C-View support that it is safe for clinical use. 3D plus C-View provides a lower dose two-view option for tomosynthesis imaging that will help radiologists reduce recall rates and find cancers, translating to reduced patient anxiety and lives saved. 162
163 THANK YOU 163
How To Compare Mammography To A 3D System
Radiology Advisory Panel Meeting Hologic Selenia Dimensions 3D System with C-View Software Module FDA Review Robert Ochs, PhD Branch Chief Mammography, Ultrasound, and Imaging Software Branch Division
More informationUNITED STATES OF AMERICA FOOD AND DRUG ADMINISTRATION + + + + + + RADIOLOGICAL DEVICES PANEL + + + October 24, 2012 8:00 a.m.
1 1 UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION + + + CENTER FOR DEVICES AND RADIOLOGICAL HEALTH MEDICAL DEVICES ADVISORY COMMITTEE + + + RADIOLOGICAL
More informationPersonalized Breast Screening Service
Frequently Asked Questions WHAT IS BREAST DENSITY? Breasts are made up of a mixture of fibrous, glandular and fatty tissue. Your breasts are considered if you have predominantly fibrous or glandular tissue
More informationHow To Decide If You Should Get A Mammogram
American Medical Women s Association Position Paper on Principals of Breast Cancer Screening Breast cancer affects one woman in eight in the United States and is the most common cancer diagnosed in women
More informationRole of the Medical Physicist in Clinical Implementation of Breast Tomosynthesis
Role of the Medical Physicist in Clinical Implementation of Breast Tomosynthesis Bob Liu, Ph.D. Department of Radiology Massachusetts General Hospital And Harvard Medical School Digital Breast Tomosynthesis
More informationHow To Write A Draft Report On Breast Cancer Screening
Health Technology Assessment Appropriate Imaging for Breast Cancer Screening in Special Populations Draft Evidence Report: & December 10, 2014 Health Technology Assessment Program (HTA) Washington State
More informationMammography. What is Mammography?
Scan for mobile link. Mammography Mammography is a specific type of breast imaging that uses low-dose x-rays to detect cancer early before women experience symptoms when it is most treatable. Tell your
More informationA Guide to Breast Imaging: The Latest Technology for Screening and Detecting Breast Cancer
A Guide to Breast Imaging: The Latest Technology for Screening and Detecting Breast Cancer Sally Herschorn, MD Associate Professor of Radiology University of Vermont College of Medicine Medical Director
More informationNational Medical Policy
National Medical Policy Subject: Breast Tomosynthesis (Digital), 3-D Mammography Policy Number: NMP 526 Effective Date: December 2013 Update: April 2016 This National Medical Policy is subject to the terms
More informationBreast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA
Breast Imaging Made Brief and Simple Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA What women are referred for breast imaging? Two groups of women are referred for
More informationD. FREQUENTLY ASKED QUESTIONS
ACR BI-RADS ATLAS D. FREQUENTLY ASKED QUESTIONS 1. Under MQSA, is it necessary to include a numeric assessment code (i.e., 0, 1, 2, 3, 4, 5, or 6) in addition to the assessment category in all mammography
More informationInfrared Thermography Not a Useful Breast Cancer Screening Tool
Contact: Jeanne-Marie Phillips Sharon Grutman HealthFlash Marketing The American Society of Breast Surgeons 203-977-3333 877-992-5470 Infrared Thermography Not a Useful Breast Cancer Screening Tool Mammography
More informationMedicare Part B. Mammograms - Updated Billing Guide for Screening and Diagnostic Tests
Mammograms - Updated Billing Guide for Screening and Diagnostic Tests This article from Medicare B News Issue 223 dated October 21, 2005 is being updated and reprinted to ensure that the Noridian Administrative
More informationSustaining a High-Quality Breast MRI Practice
Sustaining a High-Quality Breast MRI Practice Christoph Lee, MD, MSHS Associate Professor of Radiology Adjunct Associate Professor, Health Services University of Washington September 11, 2015 Overview
More informationBreast Density Legislation: Implications for primary care providers
Breast Density Legislation: Implications for primary care providers Deborah J. Rhodes MD Associate Professor of Medicine 2012 MFMER slide-1 Disclosure Relevant financial relationship(s) None Off-label
More informationAmerican College of Radiology Mammography Accreditation Program
American College of Radiology Mammography Accreditation Program Objectives Overview of the ACR Mammography Accreditation Program Interrelationship between mammography accreditation, FDA certification and
More informationHarlem Hospital Center Integrated Radiology Residency Program Mammography Educational goals and objectives
Harlem Hospital Center Integrated Radiology Residency Program Mammography Educational goals and objectives Rotation 1 (Radiology year 1/2) Knowledge Based Objectives: At the end of the rotation, the resident
More informationGreat Strides MARKEY COMPREHENSIVE BREAST CARE CENTER: SETTING A NEW STANDARD OF CARE
Great Strides MARKEY COMPREHENSIVE BREAST CARE CENTER: SETTING A NEW STANDARD OF CARE Markey Cancer Center s Comprehensive Breast Care Center is the first health care provider in Kentucky to offer new
More informationVI. FREQUENTLY ASKED QUESTIONS CONCERNING BREAST IMAGING AUDITS
ACR BI-RADS ATLAS VI. FREQUENTLY ASKED QUESTIONS CONCERNING BREAST IMAGING AUDITS American College of Radiology 55 ACR BI-RADS ATLAS A. All Breast Imaging Modalities 1. According to the BI-RADS Atlas,
More informationQ: What differentiates a diagnostic from a screening mammography procedure?
The following Q&As address Medicare guidelines on the reporting of breast imaging procedures. Private payer guidelines may vary from Medicare guidelines and from payer to payer; therefore, please be sure
More informationBreast Sonography general goal. Optimizing Breast Sonography. BUS indications -- all. Breast Sonography specific goals.
Optimizing general goal Cindy Rapp BS, RDMS, FAIUM, FSDMS University of Colorado Hospital Denver, Colorado to make a more specific diagnosis than can be made with clinical and mammographic findings alone
More information2014 Meeting of Mid-Atlantic States Radiation Control Programs March 25, 2014
2014 Meeting of Mid-Atlantic States Radiation Control Programs March 25, 2014 Interpreting Physicians Final Requirements for Interpreting Physicians Meet Initial Qualifications License Certification OR
More informationBreast Ultrasound: Benign vs. Malignant Lesions
October 25-November 19, 2004 Breast Ultrasound: Benign vs. Malignant Lesions Jill Steinkeler,, Tufts University School of Medicine IV Breast Anatomy Case Presentation-Patient 1 62 year old woman with a
More informationQuality Control of Full Field Digital Mammography Units
Quality Control of Full Field Digital Mammography Units Melissa C. Martin, M.S., FACMP, FACR, FAAPM Melissa@TherapyPhysics.com 310-612-8127 ACMP Annual Meeting Virginia Beach, VA May 2, 2009 History of
More informationEvaluation and Management of the Breast Mass. Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003
Evaluation and Management of the Breast Mass Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003 Common Presentations of Breast Disease Breast Mass Abnormal
More informationCONSOLIDATED GUIDANCE ON STANDARDS FOR THE NHS BREAST SCREENING PROGRAMME
CONSOLIDATED GUIDANCE ON STANDARDS FOR THE NHS BREAST SCREENING PROGRAMME NHSBSP Publication No 60 (Version 2) April 2005 Published by: NHS Cancer Screening Programmes The Manor House 260 Ecclesall Road
More informationBreast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies
Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies Richard Wender, MD Session code: www.worldcancercongress.org A Five Step Framework to Guide Screening
More informationWhite Paper. Study to Demonstrate Efficacy of 8MP Color Display - Mammography 1.INTRODUCTION... 2 2.PURPOSE... 2 3.METHODS... 2 4.RESULTS...
White Paper Study to Demonstrate Efficacy of 8MP Color Display - Mammography CONTENTS 1.INTRODUCTION... 2 2.PURPOSE... 2 3.METHODS... 2 4.RESULTS... 3 5.CONCLUSIONS... 5 6.REPORT FROM DR. KRUPINSKI, UNIVERSITY
More informationBREAST IMAGING FOR SCREENING AND DIAGNOSING CANCER
MEDICAL POLICY BREAST IMAGING FOR SCREENING AND DIAGNOSING CANCER Policy Number: 2015T0375N Effective Date June 1, 2015 Table of Contents BENEFIT CONSIDERATIONS COVERAGE RATIONALE APPLICABLE CODES.. DESCRIPTION
More informationMAMMOGRAPHY GOALS AND OBJECTIVES
MAMMOGRAPHY GOALS AND OBJECTIVES GOALS: After completion of the mammography rotations, the resident will be able to: 1. Demonstrate learning of the knowledge-based objectives-(practice Base Learning) 2.
More informationBreast Cancer Screening 101:
Breast Cancer Screening 101: Screening Guidelines and Imaging Modalities Robert Smith, PhD American Cancer Society Cheryl Herman, MD NAPBC Education Committee November 23, 2015 Webinar Topics - Burden
More informationVariability and Accuracy in Mammographic Interpretation Using the American College of Radiology Breast Imaging Reporting and Data System
Variability and Accuracy in Mammographic Interpretation Using the American College of Radiology Breast Imaging Reporting and Data System Karla Kerlikowske, Deborah Grady, John Barclay, Steven D. Frankel,
More informationCoronis 5MP Mammo. The standard of care for digital mammography
Coronis 5MP Mammo The standard of care for digital mammography The standard of care For thousands of women every day, details make all the difference. This understanding, along with many years of commitment
More informationThe Principles of Contrast Mammography
The Principles of Contrast Mammography Andrew Smith, Ph.D. Vice President Imaging Science, Hologic Introduction Multiple clinical studies have demonstrated that the use of screening mammography reduces
More informationProvincial Quality Management Programs for Mammography, Colonoscopy and Pathology in Ontario
Provincial Quality Management Programs for Mammography, Colonoscopy and Pathology in Ontario Quality Management Partnership Consultation Materials: Mammograp hy October 20, 2014 Table of Contents 1.0 Background
More informationFirst Warning Systems, Inc.
First Warning Systems, Inc. Breast Cancer Early Detection System US EU/UK & Russia Executive Summary September 2012 i 1. EXECUTIVE SUMMARY 1.1 FIRST WARNING SYSTEM INTRODUCTION First Warning System (FWS)
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationScreening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement
Screening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement Rebecca Ferrini, MD, Elizabeth Mannino, MD, Edith Ramsdell, MD and Linda Hill, MD, MPH Burden
More informationClinical Trials and Screening: What You Need to Know
Scan for mobile link. Clinical Trials and Screening: What You Need to Know What is a Clinical Trial? At A Glance A clinical trial is a research study that tests how well new medical techniques work in
More informationBREAST CHARACTERISTICS AND DOSIMETRIC DATA IN X RAY MAMMOGRAPHY - A LARGE SAMPLE WORLDWIDE SURVEY
BREAST CHARACTERISTICS AND DOSIMETRIC DATA IN X RAY MAMMOGRAPHY - A LARGE SAMPLE WORLDWIDE SURVEY N. GEERAERT a,b,c, R. KLAUSZ a, S. MULLER a, I. BLOCH c, H. BOSMANS b a GE Healthcare, Buc, France b Department
More informationBREAST IMAGING. Developed by the Ad Hoc Committee on Resident and Fellow Education of the Society of Breast Imaging
BREAST IMAGING Developed by the Ad Hoc Committee on Resident and Fellow Education of the Society of Breast Imaging Stephen A. Feig, M.D., Chair Ferris Hall, M.D. Debra Ikeda, M.D. Ellen Mendelson, M.D.
More informationDigital Mammography Update: Design and Characteristics of Current Systems
: Design and Characteristics of Current Systems Kalpana M. Kanal, Ph.D., DABR Assistant Professor Department of Radiology University of Washington Seattle, Washington AAPM Annual Meeting 2009 Anaheim,
More informationPrototype Internet consultation system for radiologists
Prototype Internet consultation system for radiologists Boris Kovalerchuk, Department of Computer Science, Central Washington University, Ellensburg, WA 98926-7520, USA borisk@tahoma.cwu.edu James F. Ruiz
More informationAn Action Guide for Supplemental Cancer Screening for Women with Dense Breasts: Next Steps for Patients, Clinicians, and Insurers
Supplemental Screening Tests Following Negative Mammography in Women with Dense Breast Tissue The New England Comparative Effectiveness Public Advisory Council An Action Guide for Supplemental Cancer Screening
More informationACR BI-RADS ATLAS MAMMOGRAPHY MAMMOGRAPHY II. REPORTING SYSTEM. American College of Radiology 121
ACR BI-RADS ATLAS II. REPORTING SYSTEM American College of Radiology 121 2013 122 American College of Radiology ACR BI-RADS ATLAS A. REPORT ORGANIZATION (Guidance chapter, see page 147) The reporting system
More informationCertification protocol for breast screening and breast diagnostic services
Certification protocol for breast screening and breast diagnostic services Authors N. Perry R. Holland M. Broeders H. Rijken M. Rosselli del Turco C. de Wolf This is a revised version of the original EUREF
More informationMammography Education, Inc.
Mammography Education, Inc. 2011 LÁSZLÓ TABÁR, M.D.,F.A.C.R (Hon) 3D image of a milk duct MULTIMODALITY DETECTION and DIAGNOSIS of BREAST DISEASES PRAGUE, Czech Republic Crown Plaza, Prague June 29 - July
More informationMethodologies for Evaluation of Standalone CAD System Performance
Methodologies for Evaluation of Standalone CAD System Performance DB DSFM DCMS OSEL DESE DP DIAM Berkman Sahiner, PhD USFDA/CDRH/OSEL/DIAM AAPM CAD Subcommittee in Diagnostic Imaging CAD: CADe and CADx
More informationCurrent Status and Problems of Breast Cancer Screening
Research and Reviews Current Status and Problems of Breast Cancer Screening JMAJ 52(1): 45 49, 2009 Noriaki OHUCHI,* 1,2 Akihiko SUZUKI,* 1,3 Yuu SAKURAI,* 1,4 Masaaki KAWAI,* 1 Yoko NARIKAWA,* 1 Hiroto
More informationThe American College of Radiology Stereotactic Breast Biopsy Accreditation Program: Frequently Asked Questions (Updated: August 24, 2015)
The American College of Radiology Stereotactic Breast Biopsy Accreditation Program: Frequently Asked Questions (Updated: August 24, 2015) Table of Contents Stereotactic Breast Biopsy Accreditation Program
More informationim3d S.p.A. La Ricerca fa Impresa
im3d S.p.A. La Ricerca fa 26 gennaio 2011 Alberto Bert Outline Introduction CAD COLON CAD BREAST DTS Introduction La Ricerca fa Who we are and what we do The company im3d S.p.A. is a company developing
More informationUMHS-PUHSC JOINT INSTITUTE
Imaging Biomarkers for Staging and Assessing Response to Therapy in Multiple Myeloma Qian Dong, MD. Radiology University of Michigan Wei Guo, MD. Orthopedic Oncology Peking University Second Hospital Team
More informationfor breast cancer detection
Microwave imaging for breast cancer detection Sara Salvador Summary Epidemiology of breast cancer The early diagnosis: State of the art Microwave imaging: The signal processing algorithm 2D/3D models and
More informationMQSA, FDA Regulations, and Inspections
The American College of Radiology Mammography Accreditation Program: Frequently Asked Questions (Updated: December 15, 2015) Table of Contents MQSA, FDA Regulations, and Inspections... 2 ACR Mammography
More informationBreast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.
More informationAn Action Guide for Supplemental Cancer Screening for Women with Dense Breasts: Next Steps for Patients, Clinicians, and Insurers
Supplemental Screening Tests Following Negative Mammography in Women with Dense Breast Tissue The California Technology Assessment Forum An Action Guide for Supplemental Cancer Screening for Women with
More informationMammography. For 35+ years, screenfilm has been the gold standard for breast cancer detection
Digital Mammography Upright Stereo Mammography For 35+ years, screenfilm has been the gold standard for breast cancer detection IN THE BEGINNING Mammography technology has come a long way since the first
More information2011 Radiology Diagnosis Coding Update Questions and Answers
2011 Radiology Diagnosis Coding Update Questions and Answers How can we subscribe to the Coding Clinic for ICD-9 guidelines and updates? The American Hospital Association publishes this quarterly newsletter.
More informationSegmentation of Breast Tumor from Mammographic Images Using Histogram Peak Slicing Threshold
International Journal of Computer Sciences and Engineering Open Access Research Paper Volume-4, Special Issue-1 E-ISSN: 2347-2693 Segmentation of Breast Tumor from Mammographic Images Using Histogram Peak
More informationWhat do we do about mammographic density?
What do we do about mammographic density? Sarah Vinnicombe Clinical Senior Lecturer in Cancer Imaging Ninewells Hospital Medical School s.vinnicombe@dundee.ac.uk Risk Factors for Breast Cancer Genetic
More informationMQSA and ACR Digital Breast Tomosynthesis Mammography Accreditation
US FFDM Mammography Facilities and Units MQSA and ACR Digital Breast Tomosynthesis Mammography Accreditation Pamela L. Platt, BSRT(R)(M)(CV) FDA Liaison, ACR Breast Imaging Accreditation Program In 2000
More informationRadiology Physician Performance Measurement Set
American College of Radiology/ Physician Consortium for Performance Improvement / National Committee for Quality Assurance Radiology Physician Performance Measurement Set October 2007 Radiology Work Group
More informationTest Sensitivity in the Computer-Aided Detection of Breast Cancer from Clinical Mammographic Screening: a Meta-analysis
Test Sensitivity in the Computer-Aided Detection of Breast Cancer from Clinical Mammographic Screening: a Meta-analysis Corresponding Author: Jacob Levman 1,2, PhD 1. Institute of Biomedical Engineering
More information(1) Interpreting physicians. All physicians interpreting mammograms shall meet the following qualifications:
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 900 Quality Mammography Standards Subpart B Quality Standards and Certification Sec. 900.12 Quality standards. (a) Personnel.
More informationAutomated Breast Volume Scanning 3D Ultrasound of the Breast
Automated Breast Volume Scanning 3D Ultrasound of the Breast Roel Mus, MD Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen, The Netherlands Matthieu Rutten, MD, PhD Jeroen Bosch Ziekenhuis,
More informationDigital Mammogram National Database
Digital Mammogram National Database Professor Michael Brady FRS FREng Medical Vision Laboratory Oxford University Chairman: Mirada Solutions Ltd PharmaGrid 2/7/03 ediamond aims construct a federated database
More informationIAC Ch 41, p.1. Procedure means a stereotactically guided breast biopsy performed on a patient for diagnostic purposes.
IAC Ch 41, p.1 641 41.7 (136C) X-ray machines used for stereotactically guided breast biopsy. 41.7(1) Definitions. In addition to the definitions provided in rules 641 38.2(136C), 641 40.2(136C), and 641
More informationGuideline for the Imaging of Patients Presenting with Breast Symptoms incorporating the guideline for the use of MRI in breast cancer
Guideline for the Imaging of Patients Presenting with Breast Symptoms incorporating the guideline for the use of MRI in breast cancer Version History Version Date Summary of Change/Process 0.1 09.01.11
More informationImaging Viewing Imaging Viewing Mammography Mammography
INTUITIVE PC-BASED DICOM VIEWING AND ROUTING SOLUTIONS that provide unmatched functionality, flexibility and superior data management even in the most demanding production environments. Enterprise Grade
More informationDigital Breast Tomosynthesis
Digital Breast Tomosynthesis White Paper A clinical assessment based on literature by Dr. Finn Lindhardt, senior consultant, Breast Center Regionshospitalet Viborg June 2010 This article summarizes the
More informationDigital Breast Tomosynthesis QC Requirements
Digital Breast Tomosynthesis QC Requirements AAPM Spring Clinical Meeting March 8, 2015 Michael S Glaser, MS, DABR Alliance Medical Physics, LLC Learning Objectives 1. GE SenoClaire - Physicist & Technologist
More informationDisclosure. I have the following relationships with commercial interests:
Disclosure Electra Paskett, Ph.D., MPH I have the following relationships with commercial interests: Merck Research grant, in-kind donation Pfizer Stock ownership Meridian Bioscience Stock ownership A
More informationPEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationDose Measurement in Mammography; What are we measuring? David E. Hintenlang, Ph.D. DABR University of Florida
Dose Measurement in Mammography; What are we measuring? David E. Hintenlang, Ph.D. DABR University of Florida Average Glandular Dose Required measurement performed by medical physicist as part of Mammography
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationAdditional Double Reading of Screening Mammograms by Radiologic Technologists: Impact on Screening Performance Parameters
ARTICLE Additional Double Reading of Screening Mammograms by Radiologic Technologists: Impact on Screening Performance Parameters Lucien E. M. Duijm, Johanna H. Groenewoud, Jacques Fracheboud, Harry J.
More informationUpdate on MQSA and ACR Mammography Accreditation
MQSA - Who s Who Update on MQSA and ACR Mammography Accreditation The Law: Mammography Quality Standards Act (MQSA) The Regulator: US Food and Drug Administration (FDA) Pamela L. Platt, BSRT(R)(M)(CV)
More informationSurveying and QC of Stereotactic Breast Biopsy Units for ACR Accreditation
Surveying and QC of Stereotactic Breast Biopsy Units for ACR Accreditation LORAD Stereotactic Breast Biopsy System AAPM Spring Clinical Meeting Phoenix, AZ March 17, 2013 Melissa C. Martin, M.S., FACR,
More informationFFR CT : Clinical studies
FFR CT : Clinical studies Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Denmark Disclosures: Research grants: Edwards and Siemens Coronary CTA: High diagnostic sensitivity
More informationThe Field. Radiologic technologists take x-rays and administer nonradioactive materials into patients' bloodstreams for diagnostic purposes.
Radiologic Technologist Overview The Field - Specialty Areas - Preparation - Day in the Life - Earnings - Employment - Career Path Forecast - Professional Organizations The Field Radiologic technologists
More informationConcepts for High-Resolution Low-Dose CT of the Breast
RSNA 2012 Refresher Course 721B, Chicago, Nov. 30, 2012 Concepts for High-Resolution Low-Dose CT of the Breast Disclosures WAK is founder, shareholder and CEO of CT Imaging GmbH, Erlangen, Germany. Willi
More informationDriving Forces in Health Care:
: Take This Job and Love It! Peggy Hoosier, M.Ed., RT (R) (M) Sr. Vice President of Professional Education Advanced Health Education Center,Ltd. 2011 State of 2011 Driving Forces in Health Care: Money
More informationLow-dose CT Imaging. Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital
Lung Cancer Screening with Low-dose CT Imaging Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital Despite recent declines in the incidence of lung cancer related to the
More informationBreast Biphasic Compression versus Standard Monophasic Compression in X-ray Mammography 1
Francesco Sardanelli, MD Franco Zandrino, MD Andrea Imperiale, MD Emma Bonaldo, MD Maria G. Quartini, RT Nadia Cogorno, RT Breast Biphasic Compression versus Standard Monophasic Compression in X-ray Mammography
More informationBreast MRI Quality Control
Donna M. Reeve, MS, DABR, DABMP Department of Imaging Physics Educational Objectives Discuss the importance of breast MRI quality control (QC). Provide an overview of the new ACR Breast MRI Accreditation
More informationFrequently Asked Questions about Mammography and the USPSTF Recommendations: A Guide for Practitioners
Frequently Asked Questions about Mammography and the USPSTF Recommendations: A Guide for Practitioners Wendie A. Berg, MD, PhD, FACR 1, R. Edward Hendrick, PhD, FACR 2, Daniel B. Kopans, MD, FACR 3, and
More informationPreprocessing of Screening Mammograms Based on Local Statistical Models
Preprocessing of Screening Mammograms Based on Local Statistical Models Jiří Grim Institute of Information Theory and Automation Czech Academy of Sciences P.O. BOX 18, 18208 Prague 8 Czech Republic grim@utia.cas.cz
More informationThe 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6
More informationThe American College of Radiology Breast Ultrasound Accreditation Program: Frequently Asked Questions
The American College of Radiology Breast Ultrasound Accreditation Program: Frequently Asked Questions Table of Contents APPLICATION - GENERAL... 1 MOVED FACILITIES AND UNITS... 3 EQUIPMENT... 4 PERSONNEL...
More informationMeasure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions National Quality Strategy Domain: Effective Clinical Care
Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION:
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who
More informationTraining needs for professionals in conventional radiology (radiology technicians, physicists, radiologists) joining digital radiology
Training needs for professionals in conventional radiology (radiology technicians, physicists, radiologists) joining digital radiology S Peer 1, R Peer 1, P Torbica 1, W Jaschke 1, E Vaño 2 Innsbruck University
More informationPatient Prep Information
Stereotactic Breast Biopsy Patient Prep Information Imaging Services Cannon Memorial Hospital Watauga Medical Center Table Weight Limits for each facility Cannon Memorial Hospital Watauga Medical Center
More informationNeedle crystal detector technology in mammography further dose reduction and clinical image quality with
Needle crystal detector technology in mammography further dose reduction and clinical image quality with different beam qualities (W/Rh vs. Mo/Rh) Poster No.: C-1461 Congress: ECR 2013 Type: Scientific
More informationNicole Kounalakis, MD
Breast Disease: Diagnosis and Management Nicole Kounalakis, MD Assistant Professor of Surgery Goal of Breast Evaluation The goal of breast evaluation is to classify findings as: normal physiologic variations
More informationLocal Coverage Determination (LCD): Screening and Diagnostic Mammography (L29328)
Local Coverage Determination (LCD): Screening and Diagnostic Mammography (L29328) Contractor Information Contractor Name First Coast Service Options, Inc. LCD Information Document Information LCD ID L29328
More informationKnowledge Discovery and Data Mining
Knowledge Discovery and Data Mining Lecture 15 - ROC, AUC & Lift Tom Kelsey School of Computer Science University of St Andrews http://tom.home.cs.st-andrews.ac.uk twk@st-andrews.ac.uk Tom Kelsey ID5059-17-AUC
More informationStereotactic Breast Biopsy
Scan for mobile link. Stereotactic Breast Biopsy Stereotactic breast biopsy uses mammography a specific type of breast imaging that uses low-dose x-rays to help locate a breast lump or abnormality and
More informationThe Early Detection of Breast Cancer
2007 Update Administered by the Alberta Guideline for Medical Association The Early Detection of Breast Cancer This guideline was written to provide guidance about the appropriate use of screening tools
More informationIII. REPORTING SYSTEM
ACR BI-RADS ATLAS BREAST III. REPORTING SYSTEM American College of Radiology 121 2013 122 American College of Radiology ACR BI-RADS ATLAS BREAST A. REPORT ORGANIZATION The report should be concise and
More information